Welcome to our dedicated page for Renovaro SEC filings (Ticker: RENB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lunai Bioworks Inc. filings document the public-company record for an AI-powered drug discovery and biodefense issuer with Nasdaq-listed common stock and operating assets tied to biomedical AI, BioSymetrics, and patent rights.
Recent disclosures include Current Reports on Form 8-K covering material agreements, completion of a triangular merger involving Lunai Bioworks IP, Inc. and a multi-jurisdictional patent portfolio, and special-meeting matters. Proxy materials describe stockholder votes on reverse stock split authority, adjournment mechanics, quorum and voting procedures, and related capital-structure governance. Other filing categories address material events, operating and financial results, clinical or regulatory disclosures, security registration, and changes affecting the company's name, trading symbol, and common-stock structure.
Lunai Bioworks Inc. reported a small net profit of $1.0 million for the six months ended December 31, 2025, driven mainly by a $12.0 million gain from the bankruptcy and deconsolidation of its Gedi Cube B.V. subsidiary and fair value adjustments, not by core operations.
Operating losses remained significant at $5.1 million over six months, though sharply lower than the prior-year period, and operating cash outflow was $2.4 million. At December 31, 2025, Lunai held only $491,645 in cash against a $19.5 million working capital deficit and a $509.4 million accumulated deficit, resulting in a stockholders’ deficit of $13.5 million.
Management states these conditions raise “substantial doubt” about Lunai’s ability to continue as a going concern and plans to rely on new equity or debt financing, including a November 2025 private placement where only $750,000 of the agreed funding had been received by quarter-end. Subsequent to quarter-end, Nasdaq issued a delisting determination for failure to meet the minimum bid price; Lunai has appealed, but the outcome is uncertain.
Lunai Bioworks Inc. reported a small net profit of $1.0 million for the six months ended December 31, 2025, driven mainly by a $12.0 million gain from the bankruptcy and deconsolidation of its Gedi Cube B.V. subsidiary and fair value adjustments, not by core operations.
Operating losses remained significant at $5.1 million over six months, though sharply lower than the prior-year period, and operating cash outflow was $2.4 million. At December 31, 2025, Lunai held only $491,645 in cash against a $19.5 million working capital deficit and a $509.4 million accumulated deficit, resulting in a stockholders’ deficit of $13.5 million.
Management states these conditions raise “substantial doubt” about Lunai’s ability to continue as a going concern and plans to rely on new equity or debt financing, including a November 2025 private placement where only $750,000 of the agreed funding had been received by quarter-end. Subsequent to quarter-end, Nasdaq issued a delisting determination for failure to meet the minimum bid price; Lunai has appealed, but the outcome is uncertain.
Lunai Bioworks, Inc. reported that Nasdaq staff has determined to delist its common stock from The Nasdaq Capital Market after the shares traded below the $1.00 minimum bid price for 30 consecutive business days from December 23, 2025 through February 5, 2026.
The company is not eligible for the usual 180-day cure period because it completed a 1-for-10 reverse stock split on September 30, 2025 under Nasdaq Listing Rule 5810(c)(3)(A)(iv). Lunai has requested a hearing before a Nasdaq Hearings Panel, which temporarily stays suspension and the planned Form 25 delisting filing, but there is no assurance the appeal will succeed.
Lunai Bioworks, Inc. reported that Nasdaq staff has determined to delist its common stock from The Nasdaq Capital Market after the shares traded below the $1.00 minimum bid price for 30 consecutive business days from December 23, 2025 through February 5, 2026.
The company is not eligible for the usual 180-day cure period because it completed a 1-for-10 reverse stock split on September 30, 2025 under Nasdaq Listing Rule 5810(c)(3)(A)(iv). Lunai has requested a hearing before a Nasdaq Hearings Panel, which temporarily stays suspension and the planned Form 25 delisting filing, but there is no assurance the appeal will succeed.
Lunai Bioworks Inc. reported a quarterly turnaround to net income of $2.82 million for the three months ended September 30, 2025, versus a $44.21 million loss a year ago. Results were driven by a $12.02 million gain from the bankruptcy and deconsolidation of Gedi Cube B.V., partially offset by a $6.33 million loss on extinguishment of debt and a $0.83 million long‑lived asset impairment.
Operating expenses fell to $3.31 million from $53.34 million, reflecting the absence of last year’s goodwill impairment. Cash was $624,808 and the company disclosed a working capital deficit of $18.92 million, raising substantial doubt about its ability to continue as a going concern. Total liabilities were $20.00 million and stockholders’ deficit was $(13.04) million.
During the quarter, investors converted $16.1 million of new convertible notes into 5.36 million shares at $3.00 per share following a debt exchange. The company also effected a 1‑for‑10 reverse stock split effective September 29, 2025. Common shares outstanding were 23,180,277 at September 30, 2025, and 23,432,391 as of November 10, 2025.
Lunai Bioworks Inc. reported that it has re‑established compliance with Nasdaq Listing Rule 5620(a) after holding its annual meeting of shareholders on October 31, 2025.
Nasdaq had notified the company on July 7, 2025 that it was not in compliance for not holding an annual meeting within one year of its fiscal year end. Following the October 31 meeting, Nasdaq determined the company now complies with the rule and closed the matter.
Lunai Bioworks, Inc. reported the results of its annual meeting, with stockholders approving all four proposals. Shareholders elected eight directors to serve until the 2026 annual meeting, with the election conducted in accordance with Nasdaq Listing Rule 5605(e). The company recorded 1,314,903 broker non-votes in the director elections.
On executive pay, the say‑on‑pay advisory proposal passed with 5,548,091 votes for, 2,182,131 against, and 11,760 abstentions, with 1,314,903 broker non‑votes. Stockholders also approved the appointment of Sadler as the independent registered public accounting firm with 8,836,759 for, 18,002 against, and 202,124 abstentions. Amendments to the 2023 Equity Incentive Plan were approved with 6,956,477 for, 574,336 against, 211,169 abstentions, and 1,314,903 broker non‑votes.
Lunai Bioworks reported a Nasdaq compliance notice tied to market value. On October 27, 2025, the company received notice that it no longer meets the Nasdaq Capital Market’s $35 million minimum Market Value of Listed Securities requirement after being below that level for 30 consecutive business days. Lunai has 180 calendar days, until April 27, 2026, to regain compliance by maintaining an MVLS of $35 million or more for at least 10 consecutive business days.
The notice has no immediate effect on the listing, and the common stock will continue trading on Nasdaq under the symbol LNAI. If compliance is not regained by the deadline, Nasdaq may move to delist, and the company could appeal to a Nasdaq Hearings Panel, which would stay any delisting pending a decision. Lunai Bioworks said it will monitor MVLS and may consider corporate actions during the compliance period.
Lunai Bioworks regained Nasdaq compliance with Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. Nasdaq determined the company met the standard after the closing bid price was at least $1.00 for eleven consecutive business days from September 30, 2025 to October 14, 2025.
The company had previously received notice on April 14, 2025 that it was below the minimum bid price requirement. Lunai announced the compliance update in a press release dated October 16, 2025, filed as Exhibit 99.1.
Lunai Bioworks, Inc. will hold its 2025 Annual Meeting on October 31, 2025, at 10:00 a.m. ET via live webcast. Stockholders of record on October 3, 2025 may vote on four proposals: elect four directors, a non-binding say‑on‑pay, ratify Sadler, Gibb & Associates LLC as auditor for fiscal 2026, and approve amendments to the 2023 Equity Incentive Plan.
The plan amendments would increase authorized shares to 3,476,722 (an increase of 3,042,655), add an evergreen that adjusts annually so available awards equal 15% of outstanding shares (subject to limits), add equitable adjustments, require dividends on unvested awards to accrue until vesting, prohibit option/SAR repricing without stockholder approval, clarify share counting rules, and specify change‑in‑control treatment. The Board recommends voting FOR all proposals.
There were 23,178,153 shares of common stock outstanding as of the record date. The company effected a 1‑for‑10 reverse split on September 30, 2025, and plan share figures reflect this adjustment.
Lunai Bioworks, Inc. is a pre-clinical biotechnology company that develops AI-driven multi-omic diagnostic and therapeutic tools and completed several strategic acquisitions to expand its AI and diagnostics capabilities.
The company reported a cash balance of $92,700, an accumulated deficit of $510,462,570 and a working capital deficit of $28,109,502, and discloses substantial doubt about its ability to continue as a going concern for one year after issuance of the financial statements. Lunai completed acquisitions (including Renovaro Cube and GEDi Cube) and recorded related contingent consideration and share issuances. At June 30, 2025 the company had 177,392,907 shares outstanding (up from 158,452,644 the prior year) and significant stock-based compensation expense of $3,313,291 for the year. The company also had multiple convertible and promissory notes outstanding and disclosed a subsequent debt-for-equity exchange that resulted in issuance of 53.6 million shares upon conversion of $16.1 million of convertible notes.
Lunai Bioworks Inc. received a joint Schedule 13G from Laksya Ventures Inc. and Neil Persh reporting beneficial ownership of 22,163,978 shares of common stock, representing 9.6% of 230,928,963 shares outstanding (per the issuer's Schedule 14A as of July 15, 2025). The 22,163,978 shares comprise 18,997,168 shares issued to Laksya Ventures upon conversion of convertible notes, 500,000 shares held directly by Laksya Ventures, and 2,666,810 shares held directly by Mr. Persh. Laksya Ventures is owned and controlled by Mr. Persh, who exercises sole voting and dispositive power over the reported shares. The filing includes a certification that the securities were not acquired to change or influence control of the issuer.